MX2015009819A - Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo. - Google Patents

Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.

Info

Publication number
MX2015009819A
MX2015009819A MX2015009819A MX2015009819A MX2015009819A MX 2015009819 A MX2015009819 A MX 2015009819A MX 2015009819 A MX2015009819 A MX 2015009819A MX 2015009819 A MX2015009819 A MX 2015009819A MX 2015009819 A MX2015009819 A MX 2015009819A
Authority
MX
Mexico
Prior art keywords
human
antigen
binding fragment
antibody specific
metapneumovirus
Prior art date
Application number
MX2015009819A
Other languages
English (en)
Inventor
Kenzo Takada
Kantou Nakajima
Original Assignee
Evec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evec Inc filed Critical Evec Inc
Publication of MX2015009819A publication Critical patent/MX2015009819A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención proporciona: un nuevo anticuerpo monoclonal derivado de humano que une específicamente a la proteína F del metapneumovirus humano y que neutraliza el metapneumovirus humano; un fragmento de unión al antígeno de dicho anticuerpo; y una composición farmacéutica que incluye dicho anticuerpo o dicho fragmento de unión al antígeno del mismo.
MX2015009819A 2013-01-28 2014-01-28 Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo. MX2015009819A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013013599 2013-01-28
PCT/JP2014/051866 WO2014115893A1 (ja) 2013-01-28 2014-01-28 ヒト・メタニューモウイルスに特異的なヒト抗体もしくはその抗原結合性断片

Publications (1)

Publication Number Publication Date
MX2015009819A true MX2015009819A (es) 2015-10-29

Family

ID=51227681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015009819A MX2015009819A (es) 2013-01-28 2014-01-28 Anticuerpo humano especifico a metapneumovirus humano, o fragmento de union al antigeno del mismo.

Country Status (13)

Country Link
US (1) US20150322137A1 (es)
EP (1) EP2966086A4 (es)
JP (1) JPWO2014115893A1 (es)
KR (1) KR20150135231A (es)
CN (1) CN104955839A (es)
AU (1) AU2014208456A1 (es)
BR (1) BR112015017981A2 (es)
CA (1) CA2899052A1 (es)
IL (1) IL240161A0 (es)
MX (1) MX2015009819A (es)
PH (1) PH12015501650A1 (es)
RU (1) RU2015129655A (es)
WO (1) WO2014115893A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102466763B1 (ko) * 2016-04-13 2022-11-11 오리맵스 리미티드 항- psma 항체 및 이의 용도
CN105693829B (zh) * 2016-04-14 2022-03-15 青岛易邦生物工程有限公司 一种b型禽偏肺病毒f蛋白
GB201618432D0 (en) 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
US20230085439A1 (en) * 2019-05-21 2023-03-16 University Of Georgia Research Foundation, Inc. Antibodies that bind human metapneumovirus fusion protein and their use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157003A0 (en) 2001-01-19 2004-02-08 Vironovative Bv A virus causing respiratory tract illness in susceptible mammals
CN1646684B (zh) 2002-02-21 2010-10-06 免疫医疗疫苗公司 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗
US20090087478A1 (en) 2004-12-27 2009-04-02 Progenics Pharmaceuticals (Nevada), Inc. Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them
JP4976376B2 (ja) 2005-04-08 2012-07-18 メディミューン，エルエルシー 哺乳動物メタニューモウイルスに対する抗体
KR101318611B1 (ko) 2005-07-22 2013-11-13 교와 핫꼬 기린 가부시키가이샤 유전자 재조합 항체 조성물
FR2891522B1 (fr) 2005-10-04 2009-05-08 Promiles Sa Bicyclette a longueur de cadre ajustable.
US20090304715A1 (en) 2006-03-03 2009-12-10 Tokyo University Of Science Modified antibodies with enhanced biological activities
CA2665447A1 (en) * 2006-10-04 2008-04-10 The Scripps Research Institute Human antibodies neutralizing human metapneumovirus
US8362210B2 (en) 2010-01-19 2013-01-29 Xencor, Inc. Antibody variants with enhanced complement activity
EA030319B1 (ru) 2012-03-20 2018-07-31 Хумабс Биомед Са Антитела, нейтрализующие rsv, mpv и pvm, и их применения

Also Published As

Publication number Publication date
EP2966086A1 (en) 2016-01-13
RU2015129655A (ru) 2017-03-07
WO2014115893A1 (ja) 2014-07-31
US20150322137A1 (en) 2015-11-12
EP2966086A4 (en) 2016-07-27
CN104955839A (zh) 2015-09-30
IL240161A0 (en) 2015-09-24
BR112015017981A2 (pt) 2017-11-21
PH12015501650A1 (en) 2015-10-19
KR20150135231A (ko) 2015-12-02
AU2014208456A1 (en) 2015-08-13
JPWO2014115893A1 (ja) 2017-01-26
CA2899052A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
MX2022002364A (es) Anticuerpos anti-pd-l1.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EP3702372A3 (en) Anti-cd40 human antibodies
MX2022011659A (es) Proteinas de union a antigeno que se unen a pd-l1.
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
MX2020008436A (es) Anticuerpos anti-alfa-sinucleina y metodos de uso.
EA201692458A1 (ru) Анти-gitr антитела и способы их применения
AU2016219350A8 (en) Humanized anti-MUC1* antibodies
MX2016008098A (es) Anticuerpos biespecificos del receptor 2 de factor de crecimiento ipidermico himano (her2) y metodo de uso.
SG10201900571YA (en) Anti-pd-1 antibodies
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
PH12016500940A1 (en) HUMANIZED ANTI-Tau(pS422) ANTIBODIES AND METHODS OF USE
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
MX2016009877A (es) Anticuerpos anti-baff novedosos.
EA201990672A1 (ru) Антитела, специфически связывающиеся с pd-1, и их функциональные фрагменты
MX2021002690A (es) Anticuerpos anti-avb8 y composiciones y usos de los mismos.
ZA201800804B (en) Novel anti-human gpvi antibodies and uses thereof
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
PH12015501632A1 (en) Humanized anti-hmgbi antibody or antigen-binding fragment thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2017009680A (es) Anticuerpos de dominio simple dirigidos al grupo de diferenciación 1d (cd1d).
PH12015501650A1 (en) Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof
MX2017003014A (es) Anticuerpos anti-alfa v beta 5 humanizados y usos de estos.
MX2021007421A (es) Anticuerpo que se une a factor de crecimiento endotelial vascular (vegf) y a interleucina 1 beta (il-1beta) y metodos de uso.